Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

159.79 +0.40 (+0.25%)
Streaming Delayed Price Updated: 3:45 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,477,974
Open 159.46
Bid (Size) 159.79 (2)
Ask (Size) 159.80 (1)
Prev. Close 159.39
Today's Range 159.13 - 160.29
52wk Range 143.13 - 169.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
5 Dividend Growth Stocks to Buy and Hold Forever
Dividend growth stocks offer investors a powerful combination of income and capital appreciation potential, making them attractive for long-term portfolios. 
Via The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
ETFs offer a good way to own a diversified portfolio of income-producing equities. 
Via The Motley Fool
Topics ETFs

Performance

YTD
-0.11%
-0.11%
1 Month
+3.30%
+3.30%
3 Month
+5.63%
+5.63%
6 Month
+1.22%
+1.22%
1 Year
-4.52%
-4.52%

More News

Read More
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Top Dividend ETFs That Investors can Buy and Hold for Decades
Via The Motley Fool
Topics ETFs
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Exploring NYSE:JNJ's dividend characteristics.
Via Chartmill
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
Johnson & Johnson Nears Approval for $6.5B Long Standing Talc Settlement
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
CrowdStrike: What's Ahead For Cybersecurity Player In The Wake Of Its Corporate Crisis
Via Investor's Business Daily
Nvidia Looks To Disrupt The Health Care Industry With AI
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
Via InvestorPlace
7 Dependable Dividend Stocks for Long-Term Income
Via InvestorPlace
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
Via Benzinga
Exposures COVID-19
J&J Moves Closer to Resolving Baby Powder Lawsuits, 75% of Plaintiffs Support $6.5B Settlement
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Blue-Chip Stocks to Buy on the Dip: August 2024
Via InvestorPlace
Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in August
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Nasdaq Sell-Off: 5 Unstoppable Stocks to Buy That Can Protect Your Principal and Grow Your Wealth in an Unpredictable Market
Via The Motley Fool
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024
Via InvestorPlace
3 Dividend Growth Stocks to Buy Hand Over Fist in August
Via The Motley Fool
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.